A
AKERO THERAPEUTICS INC
NASDAQ: AKRO (Akero Therapeutics, Inc.)
Kemas kini terakhir: 17 jam lalu54.55
-0.08 (-0.15%)
| Penutupan Terdahulu | 54.63 |
| Buka | 54.65 |
| Jumlah Dagangan | 4,677,618 |
| Purata Dagangan (3B) | 2,330,650 |
| Modal Pasaran | 4,490,798,592 |
| Harga / Buku (P/B) | 4.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -3.75 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.34% |
| Nisbah Semasa (MRQ) | 16.80 |
| Aliran Tunai Operasi (OCF TTM) | -262.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -177.47 M |
| Pulangan Atas Aset (ROA TTM) | -18.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Akero Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
-1.5
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -1.50 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.37% |
| % Dimiliki oleh Institusi | 109.31% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 56.00 (Jefferies, 2.66%) | Pegang |
| Median | 54.00 (-1.01%) | |
| Rendah | 54.00 (HC Wainwright & Co., -1.01%) | Pegang |
| 54.00 (Canaccord Genuity, -1.01%) | Pegang | |
| Purata | 54.67 (0.22%) | |
| Jumlah | 3 Pegang | |
| Harga Purata @ Panggilan | 54.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Oct 2025 | 54.00 (-1.01%) | Pegang | 53.88 |
| Canaccord Genuity | 09 Oct 2025 | 54.00 (-1.01%) | Pegang | 54.08 |
| Jefferies | 09 Oct 2025 | 56.00 (2.66%) | Pegang | 54.08 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ROLPH TIMOTHY | - | - | 0 | 0 |
| YOUNG JONATHAN | - | 54.35 | -9,259 | -503,227 |
| Jumlah Keseluruhan Kuantiti Bersih | -9,259 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -503,227 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 54.35 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| YOUNG JONATHAN | Pegawai | 26 Nov 2025 | Dibuang (-) | 9,259 | 54.35 | 503,227 |
| ROLPH TIMOTHY | Pegawai | 25 Nov 2025 | Pelaksanaan pilihan | 152,678 | - | - |
| YOUNG JONATHAN | Pegawai | 24 Nov 2025 | Pelaksanaan pilihan | 12,550 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Nov 2025 | Pengumuman | Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 |
| 09 Oct 2025 | Pengumuman | Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion |
| 07 Oct 2025 | Pengumuman | Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |